- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about OCGN
Recent news which mentions OCGN
23 Stocks Moving in Wednesday's Pre-Market Session
February 23, 2022
From Benzinga
73 Biggest Movers From Yesterday
February 23, 2022
From Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 22, 2022
From Benzinga
Ocugen Is Too Uncertain as Time Runs Out for Covaxin’s Approval
February 22, 2022
Tickers
OCGN
From InvestorPlace
From Benzinga
Production Updates Could Give Novavax Stock a Big Boost
February 22, 2022
From InvestorPlace
Even a Falling Nasdaq Couldn't Stop These 2 Stocks Tuesday
February 22, 2022
From Motley Fool
50 Stocks Moving In Tuesday's Mid-Day Session
February 22, 2022
From Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 22, 2022
From Benzinga
Mid-Day Market Update: Stocks Extend Losses; Dow Tumbles Over 400 Points
February 22, 2022
From Benzinga
Dear AMC Stock Fans, Mark Your Calendars for March 1
February 22, 2022
From InvestorPlace
Chinese Stocks Alert: Why Are BABA, TCEHY, JD, PDD Stocks Down Today?
February 22, 2022
From InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 22, 2022
From Benzinga
FDA Lifts Clinical Hold On Ocugen's COVID-19 Vaccine Study In US
February 22, 2022
Tickers
OCGN
From Benzinga
From InvestorPlace
Russia-Ukraine conflict is a worry, but this is still the biggest threat for stock investors, says JPMorgan
February 22, 2022
From MarketWatch
30 Stocks Moving in Tuesday's Pre-Market Session
February 22, 2022
From Benzinga
Despite an 80% Drop, Ocugen Stock Is Still Too Pricey
February 21, 2022
Tickers
OCGN
From InvestorPlace
From InvestorPlace
Americans’ Appetite for Vaccine Options Bodes Well for Ocugen
February 21, 2022
From InvestorPlace
Ocugen Stock Is a Fairy Tale in Need of a Happy Ending
February 18, 2022
From InvestorPlace
2 Popular Robinhood Stocks to Sell Right Now
February 18, 2022
From Motley Fool
Novavax Stock Is at Risk Despite Positive Poll Results
February 16, 2022
From InvestorPlace
Why Novavax, Dynavax, and Ocugen Are All Rising Today
February 15, 2022
From Motley Fool
Two Reasons to Skip Ocugen Stock Despite Some Good News
February 09, 2022
Tickers
OCGN
From InvestorPlace
With No Vaccine Approval, Ocugen Is the Definition of Dead Money
February 09, 2022
Tickers
OCGN
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.